Loading...
OTCM
AOBI
Market cap0kUSD
Jun 22, Last price  
0.00USD
Name

American Oriental Bioengineering Inc

Chart & Performance

D1W1MN
OTCM:AOBI chart
P/E
P/S
0.00
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-16.34%
Revenues
145m
-31.78%
22,7057,840,00010,200,00020,863,00031,967,00054,733,000110,182,000160,482,000264,643,000296,151,000305,944,000212,690,000145,100,000
Net income
-60m
L-12.82%
-537,5811,316,0001,127,0004,602,0007,771,00013,426,00029,201,00043,291,00047,060,00041,421,00014,087,000-68,491,000-59,713,000
CFO
-46m
L
-376,233-15,4052,021,4012,719,6668,395,24111,616,08629,093,46445,099,37977,758,71725,408,6328,033,25329,955,718-46,453,319

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

American Oriental Bioengineering, Inc. (AOBI), headquartered in Beijing, China, focuses its operations on the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical and healthcare products. The company's core pharmaceutical offerings include a range of prescription medications. Among these are the Shuanghuanglian Lyophilized Injection Powder (SHL brand), prescribed to treat flu symptoms such as elevated fever, coughs, and sore throats, as well as to address upper respiratory tract infections, mild pneumonia, bronchitis, and tonsillitis. Another significant prescription product is the Cease Enuresis Soft Gel (CE Gel brand), formulated to alleviate bedwetting. AOBI's portfolio also extends to various over-the-counter (OTC) pharmaceutical solutions. These feature the Cease Enuresis Patch for managing bedwetting and urinary incontinence; Jinji Capsule, used for conditions like endometritis, annexitis, and pelvic inflammations; Jinji Yimucao, designed to relieve premenstrual syndrome (PMS) and other related menstrual and menopausal discomforts; and Boke Nasal Spray, which offers relief for sinus congestion associated with the common cold, nasal stuffiness, chronic rhinitis, allergic rhinitis, and nasosinusitis. Furthermore, the company develops and markets a selection of nutraceutical products, notably including soybean peptide-based items available as beverages, tablets, powders, and instant coffee. Beyond its manufacturing activities, AOBI is also involved in the wholesale and retail distribution of both its pharmaceutical and nutraceutical goods. The company's products are sold across the People's Republic of China through both direct channels and a network of distributors, reaching hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical retailers, and various other retail outlets.
IPO date
Dec 18, 2006
Employees
3,719
Domiciled in
CN
Incorporated in
US

Valuation

No data to show